Last reviewed · How we verify
m-FOLFOX-6 regimen
At a glance
| Generic name | m-FOLFOX-6 regimen |
|---|---|
| Sponsor | Arcus Biosciences, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of 5-fluorouracil (5-FU) in Patients With Metastatic Colorectal Cancer (PHASE2)
- Protective Effect of N-acetylcysteine on Oxaliplatin-Induced Neuropathy in Colorectal Cancer (NA)
- An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer. (PHASE1, PHASE2)
- Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer (PHASE2)
- A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer (PHASE2)
- A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 in Gastric/Gastroesophageal Cancer (PHASE1)
- A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer (PHASE1, PHASE2)
- Combination Chemotherapy for 3 Months or 6 Months in Treating Patients With Stage III Colon Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |